Cervical Intraepithelial Neoplasia (CIN) Pipeline Review, H1 2017 - 8 Companies & Drug Profile Activities - Research and Markets

DUBLIN--()--The "Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2017" report has been added to Research and Markets' offering.

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 3 and 1 molecules, respectively.

Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Cervical Intraepithelial Neoplasia (CIN) - Overview
  3. Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
  • CEL-SCI Corp
  • CritiTech Inc
  • Genexine Inc
  • PDS Biotechnology Corp
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • THEVAX Genetics Vaccine USA Inc
  • Transgene SA
  • Vaccibody AS

For more information about this report visit https://www.researchandmarkets.com/research/nkw4xp/cervical

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cervical Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cervical Cancer Drugs